Share on StockTwits

Equities researchers at JPMorgan Chase & Co. upped their price objective on shares of Tornier NV (NASDAQ:TRNX) from $20.00 to $23.00 in a research report issued on Friday. JPMorgan Chase & Co.’s price target would suggest a potential upside of 5.84% from the stock’s previous close.

A number of other analysts have also recently weighed in on TRNX. Analysts at Barclays raised their price target on shares of Tornier NV from $26.00 to $28.00 in a research note on Friday. Separately, analysts at BMO Capital Markets upgraded shares of Tornier NV from a “market perform” rating to an “outperform” rating in a research note on Friday. They now have a $24.00 price target on the stock, up previously from $20.00. Finally, analysts at TheStreet upgraded shares of Tornier NV from a “sell” rating to a “hold” rating in a research note on Friday, June 6th. Three investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. The stock has an average rating of “Hold” and a consensus price target of $22.67.

Shares of Tornier NV (NASDAQ:TRNX) traded up 11.49% during mid-day trading on Friday, hitting $21.73. The stock had a trading volume of 541,015 shares. Tornier NV has a 52-week low of $15.17 and a 52-week high of $24.35. The stock’s 50-day moving average is $22.29 and its 200-day moving average is $20.51. The company’s market cap is $1.055 billion.

Tornier NV (NASDAQ:TRNX) last issued its quarterly earnings data on Thursday, August 7th. The company reported ($0.20) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.16) by $0.04. The company had revenue of $86.85 million for the quarter, compared to the consensus estimate of $79.40 million. During the same quarter in the prior year, the company posted ($0.28) earnings per share. The company’s quarterly revenue was up 11.2% on a year-over-year basis. On average, analysts predict that Tornier NV will post $-0.45 earnings per share for the current fiscal year.

Tornier N.V. (NASDAQ:TRNX) is a global medical device company focused on surgeons that treat musculoskeletal injuries and disorders of the shoulder, elbow, wrist, hand, ankle and foot.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.